Literature DB >> 32209164

Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020.

Emanuele Nicastri1,2, Alessandra D'Abramo1,2, Giovanni Faggioni3, Riccardo De Santis3, Andrea Mariano1, Luciana Lepore1, Filippo Molinari3, Giancarlo Petralito3, Silvia Fillo3, Diego Munzi3, Angela Corpolongo1, Licia Bordi1, Fabrizio Carletti1, Concetta Castiletti1, Francesca Colavita1, Eleonora Lalle1, Nazario Bevilacqua1, Maria Letizia Giancola1, Laura Scorzolini1, Simone Lanini1, Claudia Palazzolo1, Angelo De Domenico4, Maria Anna Spinelli3, Paola Scognamiglio1, Paolo Piredda4, Raffaele Iacomino4, Andrea Mone4, Vincenzo Puro1, Nicola Petrosillo1, Antonio Battistini5, Francesco Vairo1, Florigio Lista3,6, Giuseppe Ippolito1,6.   

Abstract

Data concerning the transmission of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) in paucisymptomatic patients are lacking. We report an Italian paucisymptomatic case of coronavirus disease 2019 with multiple biological samples positive for SARS-CoV-2. This case was detected using the World Health Organization protocol on cases and contact investigation. Current discharge criteria and the impact of extra-pulmonary SARS-CoV-2 samples are discussed.

Entities:  

Keywords:  COVID-19; Italy; paucisymptomatic case

Mesh:

Substances:

Year:  2020        PMID: 32209164      PMCID: PMC7096776          DOI: 10.2807/1560-7917.ES.2020.25.11.2000230

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing human disease named coronavirus disease (COVID-19) was identified in Wuhan, China, in December 2019 [1]. The number of affected patients rapidly increased and, as at 16 March 2020, more than 165,000 cases were reported (including 6,507 deaths) both in and outside of China [2]. The early identification of imported cases has a crucial role in preventing secondary transmission and it is based on both epidemiological and clinical assessment [3,4]. We report an Italian paucisymptomatic case of COVID-19 with multiple biological samples positive for SARS-CoV-2. On 3 February 2020, 56 asymptomatic Italian citizens were medically evacuated from Wuhan, China to Rome, Italy for a 14-day quarantine period spent in the Cecchignola military complex. Before leaving Wuhan, all subjects were afebrile and asymptomatic. During the flight, they wore facial masks and proper hand hygiene was prescribed. On 5 February, according to the World Health Organization (WHO) protocol on cases and contact investigation [5], all of them were screened for SARS-CoV-2 RNA by the Scientific Department of the Italian Army Medical Center using real-time RT-PCR on nasopharyngeal swabs. Only one swab resulted positive both for the envelope protein gene E and the RNA-dependent RNA polymerase gene RdRp [6].

Case description

The individual who tested positive was an Italian man in his late 20s, in healthy condition. He was in Wuhan from 20 January to 3 February to visit his Chinese friends. He had no exposure to marketplaces, live animals, known sick people or access to healthcare facilities. In order to avoid SARS-CoV-2 infection, he stayed at home except for a 1-day walk in the town district. His close contacts were the three members of the Chinese family hosting him, who are still in healthy condition. On 6 February, the case was admitted to the Isolation Unit of the National Institute for Infectious Diseases ‘Lazzaro Spallanzani’ for isolation and clinical assessment, with a transient mild conjunctivitis and a body temperature of 37.3 °C. Laboratory findings were all within normal values and common respiratory pathogens (influenzavirus A and B, parainfluenza virus, respiratory syncytial virus, rhinovirus, adenovirus, enterovirus, metapneumovirus, bocavirus, coronavirus strains HKU1, NL63, 229E and OC43, Bordetella pertussis, Mycoplasma pneumoniae and Legionella pneumophila) on pharyngeal swab were excluded. At admission, a second positive real-time RT-PCR on a nasopharyngeal swab confirmed the COVID-19 diagnosis. As the patient was paucisymptomatic, we retrospectively tested serum samples collected at admission using in house-prepared immunofluorescence (IF) slides and neutralisation test as confirmatory test. The IF results showed positivity for both IgG and IgM (≥ 1:640 and 1:80, respectively) at the same time point of the first viral RNA positive result. A preliminary evaluation of the IF test was performed using residual negative samples and few serum samples positive for other human coronaviruses. Two chest computed tomography (CT) scans of the patient (on 7 and 17 February) were normal. On 7 February, off-label oral treatment with lopinavir/ritonavir (400/100 mg every 12 h) was started after obtaining written informed consent [7]. SARS-CoV-2 RNA in stools, nasopharyngeal and oropharyngeal swabs resulted positive at different time points, whereas urine, spermatic fluid, saliva, blood and conjunctival swabs were persistently negative (Table).
Table

Virological and clinical characteristics, COVID-19 patient, Italy, February 2020

February56789101112131415161718
Real-time RT-PCR SARS-CoV-2 RNA
Naso- and oropharyngeal swab + + + + + + + + + +
StoolSampleNANA + +NA + + + +
Clinical characteristics
BT (°C)36.537.337.137.136.837.13736.836.636.736.836.936.236.1
Signs/symptomsMildconjunctivitisTonsillar exudateTonsillar exudate
LPV/r treatment + + + + + + + + + + + +

+: positive; −: negative; BT: body temperature; COVID-19: coronavirus disease 2019; LPV/r: lopinavir/ritonavir; NA: not available; SARS-COV-2: SARS-coronavirus-2.

+: positive; −: negative; BT: body temperature; COVID-19: coronavirus disease 2019; LPV/r: lopinavir/ritonavir; NA: not available; SARS-COV-2: SARS-coronavirus-2. On 12 and 13 February, two nasopharyngeal swabs resulted negative for SARS-CoV-2 RNA. Nevertheless, on 14 February, a transient whitish exudate on the right palatal tonsil was observed and the oropharyngeal swabs were negative for bacterial growth and again positive for SARS-CoV-2 RNA. No other laboratory finding was remarkable. The exudate disappeared within 48 h. On 22 February, the patient continued to be asymptomatic and afebrile; the isolation regimen was stopped and the patient discharged. No other COVID–19 case was observed in the 55 Italian citizens at quarantine. They were discharged at the end of 14-day quarantine after obtaining two SARS-CoV-2 negative samples 24 hours apart near or on the completion of the period.

Discussion

We present a detailed report of a paucisymptomatic COVID-19 patient with biological samples consecutively collected from different sites. To our knowledge, a previous asymptomatic case in a 10-year old boy, part of a COVID-19 family cluster, with ground-glass lung opacities at chest CT scan has been reported [8]. Our patient was tested for SARS-CoV-2 within the WHO contact protocol applied to the 56 Italians medically evacuated from Wuhan. Otherwise, with no clear exposure or direct contact with possible sources of SARS-CoV-2 infection, he would not have been included in the COVID-19 case definition and not considered for viral screening [5]. Moreover, considering the limited data available at the time on treatment and clinical outcome in COVID-19 patients, an early and off-label treatment with oral lopinavir/ritonavir was started and it could have affected the natural course of the disease. A Chinese familial cluster of five patients with COVID-19 pneumonia infected by an asymptomatic carrier has also been described [9]. Two further cases have been reported who transmitted virus during the pre-symptomatic phase and eventually developed fever and respiratory symptoms [10]. It is important to highlight that in our case, the patient, still undiagnosed, did probably not transmit the SARS-CoV-2 infection to his asymptomatic Chinese close contacts and to the other 55 Italian citizens. Finally, the patient presented persistent viral shedding in stools despite the lack of any gastrointestinal signs and symptoms. In a previous study, the presence of SARS-CoV-2 RNA in faeces was associated with gastrointestinal symptoms [11]. The evidence of extrapulmonary detection of viral RNA in both symptomatic and asymptomatic subjects is of clinical interest in terms of pathogenesis and routes of transmission. However, our results are limited to the molecular detection that does not necessarily mean that infectious virus was present. Additional studies, such as virus culture, should be done to investigate potential infectiousness. According to the recommendations from WHO, the United States Centers for Disease Control and Prevention and the European Center for Disease Prevention and Control, at least two sequential respiratory tract specimens, collected at least 24 h apart, are required for discharge criteria in clinically recovered patients [12-14]. Nevertheless, our findings suggest that, even in paucisymptomatic patients, consecutive multiple-site biological samples may be required in settings with limited community transmission for discontinuation of infection control and transmission-based isolation precautions.

Conclusion

This paucisymptomatic case with detailed clinical and virological results is likely to impact on the clinical management of COVID-19 in settings with limited community transmission. Further studies are needed to better understand the clinical spectrum of COVID-19 at hospital and community levels, the role of pauci-/asymptomatic subjects in viral transmission and the clinical relevance of viral persistence in non-respiratory samples as potential sources of SARS-CoV-2 spread.
  8 in total

1.  Presumed Asymptomatic Carrier Transmission of COVID-19.

Authors:  Yan Bai; Lingsheng Yao; Tao Wei; Fei Tian; Dong-Yan Jin; Lijuan Chen; Meiyun Wang
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV).

Authors:  Guangdi Li; Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2020-03       Impact factor: 84.694

4.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.

Authors:  Camilla Rothe; Mirjam Schunk; Peter Sothmann; Gisela Bretzel; Guenter Froeschl; Claudia Wallrauch; Thorbjörn Zimmer; Verena Thiel; Christian Janke; Wolfgang Guggemos; Michael Seilmaier; Christian Drosten; Patrick Vollmar; Katrin Zwirglmaier; Sabine Zange; Roman Wölfel; Michael Hoelscher
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

5.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

7.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01

8.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

  8 in total
  32 in total

1.  Emergency department response to COVID-19 outbreak with a fever screening station and "graded approach" for isolation and testing.

Authors:  Julia Chia-Yu Chang; You-Hsu Chen; Meng-Chen Lin; Yi-Jing Li; Teh-Fu Hsu; Hsien-Hao Huang; David Hung-Tsang Yen
Journal:  J Chin Med Assoc       Date:  2020-09-02       Impact factor: 2.743

2.  COVID-19 Diffusion Before Awareness: The Role of Football Match Attendance in Italy.

Authors:  Vincenzo Alfano
Journal:  J Sports Econom       Date:  2022-06

3.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study.

Authors:  Giovanni Guaraldi; Marianna Meschiari; Alessandro Cozzi-Lepri; Jovana Milic; Roberto Tonelli; Marianna Menozzi; Erica Franceschini; Gianluca Cuomo; Gabriella Orlando; Vanni Borghi; Antonella Santoro; Margherita Di Gaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Luca Corradi; Riccardo Fantini; Ivana Castaniere; Luca Tabbì; Massimo Girardis; Sara Tedeschi; Maddalena Giannella; Michele Bartoletti; Renato Pascale; Giovanni Dolci; Lucio Brugioni; Antonello Pietrangelo; Andrea Cossarizza; Federico Pea; Enrico Clini; Carlo Salvarani; Marco Massari; Pier Luigi Viale; Cristina Mussini
Journal:  Lancet Rheumatol       Date:  2020-06-24

4.  A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.

Authors:  Salma AlBahrani; Jaffar A Al-Tawfiq; Abdulaziz R Alshaer; Amal Shilash; Khalid Alswefy; Razan Salamah Al-Zayer; Amr Mohamed Abouelela
Journal:  J Epidemiol Glob Health       Date:  2021-01-22

5.  A simplified math approach to predict ICU beds and mortality rate for hospital emergency planning under Covid-19 pandemic.

Authors:  Davide Manca; Dario Caldiroli; Enrico Storti
Journal:  Comput Chem Eng       Date:  2020-06-04       Impact factor: 3.845

6.  Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples.

Authors:  Anne J Jääskeläinen; Eliisa Kekäläinen; Hannimari Kallio-Kokko; Laura Mannonen; Elisa Kortela; Olli Vapalahti; Satu Kurkela; Maija Lappalainen
Journal:  Euro Surveill       Date:  2020-05

7.  Clinical characteristics and risk factors of mild-to-moderate COVID-19 patients with false-negative SARS-CoV-2 nucleic acid.

Authors:  Yan Rong; Fei Wang; Jing Liu; Yang Zhou; Xiaoli Li; Xinhua Liang; Dandan Zhang; Huadong Zeng; Jing Wang; Yi Shi
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

8.  Sleep and wake impairment in patients with SARS-CoV2 infection.

Authors:  Claudio Liguori; Matteo Spanetta; Loredana Sarmati; Novella Cesta; Gabriella Pezzuto; Grazia Genga Mina; Paola Rogliani; Mariangela Pierantozzi
Journal:  Sleep Med       Date:  2020-07-17       Impact factor: 3.492

9.  Gastrointestinal tract diseases as a risk factor for SARSCoV2 rectal shedding? An Italian report on 10 COVID-19 patients.

Authors:  Angela Patrì; Biagio Pinchera; Lorenzo Spirito; Mario Delfino; Ciro Imbimbo; Paola Salvatore; Ivan Gentile; Gabriella Fabbrocini
Journal:  Intest Res       Date:  2020-11-06

10.  Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis.

Authors:  Jingjing He; Yifei Guo; Richeng Mao; Jiming Zhang
Journal:  J Med Virol       Date:  2020-08-13       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.